Strata Critical Medical (SRTA) Q1 2026 earnings review
Pure-Play Medical Transition Delivers GAAP Profitability, Despite Logistics Headwinds
Strata Critical Medical's first quarter as a fully integrated, pure-play medical platform shows structural improvements paying off. Total revenue surged 87.4% YoY to $67.4 million, driven by organic logistics growth and the Keystone acquisition. Crucially, the company turned a GAAP Net Income profit of $2.4 million and generated positive operating cash flow of $3.9 million, reversing prior cash burn trends. However, sequential performance reveals emerging friction: Adjusted EBITDA decelerated to $6.4 million from $7.0 million in Q4 2025, heavily impacted by a 220-basis-point margin compression in the core Logistics segment due to customer mix and winter weather.
🐂 Bull Case
The company officially crossed into positive operating cash flow ($3.9M), proving the post-divestiture, asset-light economic model works. Free Cash Flow (before aircraft acquisitions) hit $2.1M.
The Clinical division is accelerating, growing gross profit 29.2% sequentially vs Q4 2025. Transplant Clinical revenue jumped 26.7% in a single quarter.
🐻 Bear Case
Despite 32.4% YoY revenue growth, Logistics gross margin fell sequentially from 21.5% to 19.3% due to shorter trip distances, eroding overall profitability.
Winter storms caused multi-day airport closures, driving a 3.3% sequential decline in Logistics revenue. The asset-light model does not immunize the top line from severe weather.
⚖️ Verdict: 🟢
Bullish. The strategic pivot to a pure-play medical logistics company has successfully inflected the bottom line to GAAP profitability and positive cash flow. While Logistics margins experienced sequential deceleration, the Clinical segment's robust growth and ongoing M&A execution provide a clear path to achieving reiterated FY26 guidance.
Key Themes
Clinical Segment Growth Accelerating
The integration of the Clinical business (post-Keystone acquisition) is driving aggressive margin and revenue expansion. Clinical revenue rose 12.7% sequentially to $19.8M in Q1 2026, outperforming the core Logistics segment. More importantly, Clinical gross margin expanded 320 basis points from 21.8% in Q4 2025 to 25.0% in Q1 2026. This mix shift toward high-margin surgical recovery and Normothermic Regional Perfusion (NRP) is the primary engine offsetting Logistics weakness.
Operating Cash Flow Reversing to Positive
A major de-risking milestone was achieved: Operating Cash Flow reversed from a massive $8.3M burn in Q4 2025 to a positive $3.9M generation in Q1 2026. The quality of earnings is improving as transaction-related outflows clear. Free Cash Flow (before discretionary aircraft/engine acquisitions) landed at $2.1M, giving management self-sustaining capital to fund its aggressive M&A strategy without dilutive financing.
M&A Playbook Scaling
Management continues to execute its stated M&A roll-up strategy, completing the bolt-on acquisition of Ohio Valley Perfusion Associates for approximately $1M. This expands perfusion services footprint in Ohio and Pennsylvania. With $58.8M in cash and a highly active pipeline, capital deployment toward accretive targets is poised to supplement organic mid-teens growth.
Logistics Margin Squeeze Contradicts Top-Line Growth
Despite Logistics revenue growing an impressive 32.4% YoY, the segment's profitability profile is decelerating. Logistics gross margin dropped 220 basis points sequentially (to 19.3% from 21.5% in Q4). Management cited a mix shift toward shorter trip distances. This indicates that while Strata is winning volume, the unit economics of those new/shorter routes are significantly less favorable than the historical average.
SG&A Creep Pressuring EBITDA
Adjusted SG&A increased sequentially to $9.2M (from $8.9M in Q4 2025), rising to 13.7% of revenue. While down massively from 20.6% a year ago, the sequential 30-bps increase contributed directly to total Adjusted EBITDA margin falling from 10.4% in Q4 to 9.5% in Q1. Management cited investments in resources and infrastructure, which must be monitored to ensure overhead doesn't outpace the newly acquired clinical revenue streams.
Weather Remains Uncontrollable Variable
The 3.3% sequential decline in Logistics revenue was partially blamed on severe winter storms forcing multi-day closures of key airports. Despite the asset-light model and the shift to medical logistics, Strata remains exposed to physical aviation realities. Groundings directly halt revenue generation, underscoring the limits of predictability in the core logistics division.
Macro Tailwinds: NRP and Industry Volumes Rebounding
Management explicitly noted a mid-single-digit sequential increase in deceased donors industry-wide. More importantly, the continued penetration of Normothermic Regional Perfusion (NRP) into Donation after Circulatory Death (DCD) donors is serving as a structural macro tailwind. Strata's market leadership in NRP positions it to capture an outsized share of this technological shift.
Other KPIs
Accelerating dramatically. Grew 26.7% sequentially from $7.76M in Q4 2025. This proves the cross-selling thesis is working: legacy logistics clients are adopting Strata's higher-margin clinical and surgical recovery services at a rapid pace.
Reversing. A massive swing from a $5.4 million loss in Q4 2025 and a $1.6 million loss in Q1 2025. This was aided by $3.4M in favorable fair value changes of assets/liabilities, but the underlying operating loss also shrank to $2.9M from $5.7M a year ago.
Stable. The company spent $3.7M to acquire one additional aircraft, bringing the owned fleet to 10 aircraft (out of ~35 total). This aligns with management's strategy of targeted ownership to unlock new hubs, such as the newly opened Chicago location.
Guidance
Stable. Reiterated guidance implies a 35% YoY growth at the midpoint ($267.5M) compared to FY25 continuing operations revenue ($197.1M). Q1's $67.4M run-rate perfectly tracks toward achieving this target, requiring no significant second-half heroism.
Stable. Reiterated. The midpoint of $31 million implies dramatic acceleration from FY25's $14.1 million. With $6.4 million booked in Q1, the company needs to average $8.2 million per quarter going forward, implying margin expansion is required in Q2-Q4.
Stable. Reiterated. Implies massive cash flow acceleration in the coming quarters. Achieving $2.1M in Q1 means the company must drastically ramp cash generation to hit the $18.5M midpoint, likely banking on working capital normalization and the absence of transaction costs.
Key Questions
Permanence of Logistics Squeeze
Logistics gross margin compressed by 220 basis points sequentially due to 'shorter trip distances'. Is this shorter trip profile a permanent feature of the new customer cohorts onboarded this year, or a temporary anomaly?
EBITDA Ramp Feasibility
With $6.4M in Q1 Adjusted EBITDA, achieving the $31M FY26 midpoint requires averaging over $8M per quarter for the rest of the year. What specific cost levers or margin expansions give you confidence in that sequential ramp?
Integration Costs vs Synergies
Adjusted SG&A grew sequentially as a percentage of revenue. As you continue your M&A playbook (like Ohio Valley Perfusion), when should investors expect corporate overhead to flatten and SG&A leverage to materialize?